PCM
RLAY icon

Penserra Capital Management’s Relay Therapeutics RLAY Stock Holding History

Penserra Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,115
Closed -$66K – 1519
2021
Q3 		$66K Buy
2,115
+10
+0.5% +$337 ﹤0.01% 964
2021
Q2 		$77K Buy
2,105
+70
+3% +$2.31K ﹤0.01% 877
2021
Q1 		$70K Sell
2,035
-30
-1% -$1.3K ﹤0.01% 761
2020
Q4 		$85K Buy
+2,065
New +$93.3K ﹤0.01% 613

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Penserra Capital Management's RLAY Position: Q4 2021 in Review

Penserra Capital Management sold out of Relay Therapeutics (RLAY) in Q4 2021, closing a stake of 2,115 shares — an estimated $66K sold.

Penserra Capital Management first reported a position in RLAY in Q4 2020 and held it in 4 quarters. The position peaked at $85K in Q4 2020. 131 funds tracked by Wall St. Rank hold RLAY as of Q4 2021.

  • Penserra Capital Management reported no remaining Relay Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 2,115 Relay Therapeutics shares in Q4 2021, an estimated $66K.
  • Penserra Capital Management first reported a position in Relay Therapeutics in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Relay Therapeutics position peaked at $85K in Q4 2020.
  • 131 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.